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Abstract: Artemether (ARTM) is a very effective antimalarial drug with poor solubility and 
consequently low bioavailability. Smart nanocrystals of ARTM with particle size of 161±1.5 nm 
and polydispersity index of 0.172±0.01 were produced in ,1 hour using a wet milling technology, 
Dena® DM-100. The crystallinity of the processed ARTM was confirmed using differential 
scanning calorimetry and powder X-ray diffraction. The saturation solubility of the ARTM 
nanocrystals was substantially increased to 900 µg/mL compared to the raw ARTM in water 
(145.0±2.3 µg/mL) and stabilizer solution (300.0±2.0 µg/mL). The physical stability studies 
conducted for 90 days demonstrated that nanocrystals stored at 2°C–8°C and 25°C were very 
stable compared to the samples stored at 40°C. The nanocrystals were also shown to be stable 
when processed at acidic pH (2.0). The solubility and dissolution rate of ARTM nanocrystals 
were significantly increased (P,0.05) compared to those of its bulk powder form. The results of 
in vitro studies showed significant antimalarial effect (P,0.05) against Plasmodium falciparum 
and Plasmodium vivax. The IC
50
 (median lethal oral dose) value of ARTM nanocrystals was 
28- and 54-fold lower than the IC
50
 value of unprocessed drug and 13- and 21-fold lower than 
the IC
50
 value of the marketed tablets, respectively. In addition, ARTM nanocrystals at the same 
dose (2 mg/kg) showed significantly (P,0.05) higher reduction in percent parasitemia (89%) 
against P. vivax compared to the unprocessed (27%), marketed tablets (45%), and microsuspen-
sion (60%). The acute toxicity study demonstrated that the LD
50
 value of ARTM nanocrystals 
is between 1,500 mg/kg and 2,000 mg/kg when given orally. This study demonstrated that 
the wet milling technology (Dena® DM-100) can produce smart nanocrystals of ARTM with 
enhanced antimalarial activities.
Keywords: artemether, milling, smart nanocrystals, nanosuspension, in vitro dissolution, 
antimalarial activity
Introduction
Until the middle of the 20th century, malaria was a disease without any effective 
treatments. Even today, malaria remains endemic in specific regions of the world, 
with large numbers of deaths related to this disease.1 According to the latest World 
Health Organization (WHO) report, which was released in October 2015, there were 
438,000 deaths due to malaria, with ~214 million cases of malaria also diagnosed 
between the years 2000 and 2015.
It has become evident from the recent report that the global rates of infection and 
mortality in the period 2000–2015 have been declining to 37% and 60%, respec-
tively. In 2015, the highest number of malaria cases with .90% of the reported 
deaths being ascribed to malaria were reported in Sub-Saharan Africa. Among the 
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deaths, ~70% of the victims were children whose ages 
were ,5 years. However, in the period 2000–2015, the death 
tolls have been decreasing owing to the introduction of new 
antimalarial therapies.2
Malaria is caused by a parasitic protozoan (a unicellular 
microorganism) of the genus Plasmodium. Plasmodium 
falciparum (malaria tropica), Plasmodium vivax (malaria 
tertian), and Plasmodium malariae and Plasmodium ovale 
(malaria quaterna) are the species responsible for transmission 
of the disease in humans.3 The parasite is transmitted into 
the circulatory system from the bite of an infected female 
Anopheles mosquito. It then travels to the liver where it matures 
and reproduces.4–6 According to the recent WHO report, the 
prevalence of malaria due to P. vivax and P. falciparum is 
increasing every year, with P. vivax being responsible for 
transmitting ~75% (previously 64%) of malarial infections. 
Only 25% (previously 36%) of these infections are caused 
by P. falciparum, but with both stated species being reported 
among the most common in Pakistan.7
It has become evident from the current study that 70% 
of malaria cases in Pakistan are caused by P. vivax. In addi-
tion, Khyber Pakhtunkhwa (KP) and Federally Administered 
Tribal Areas of Pakistan have been reported as the most 
vulnerable zones for P. vivax and P. falciparum, which has 
been accentuated by free movement of the Afghan refugees 
and internally displaced people (WHO report).8 It has also 
been reported that the local residents of KP and Federally 
Administered Tribal Areas are immunologically more 
resistant to malarial infections compared to the migrating 
Afghani population.9
A number of medications have been used to treat malaria, 
including quinine, quanidine, chloroquine, primaquine, halo-
fantrine (related quinolone), and pyrimethamine.10 However, 
the parasite is reported to have evolved to be resistant to 
most of these drugs. Under these circumstances, the use of 
artemisinin and its derivatives such as dihydroartemisinin, 
artesinuate, arteether, artemether (ARTM), and lumefantrine 
has been suggested by the WHO. A report published by the 
WHO in 2010 revealed that the numbers of deaths attributed 
to malaria in 2010 was markedly reduced owing to the use of 
artemisinin derivatives either individually or in combination 
therapies.11 Among the artemesinin derivatives, ARTM and 
its partner drug lumefantrine have been reported to be the 
most effective drugs to treat malaria.12–15
Artemisinin was originally isolated from the Chinese 
herb (qinghaosu), which is also known as Artemisia annua. 
The important part of its structure is the 1,2,4-trioxane ring 
(Figure 1), which is the active pharmacophore of this com-
pound and responsible for its antimalarial activity.16
ARTM shows rapid onset of schizontocidal action, 
and its metabolism in the liver produces the demethylated 
derivative dihydroartemisinin. It has demonstrated a sig-
nificant antimalarial activity against both P. falciparum 
and uncomplicated malaria. It has also been reported to be 
very effective against cerebral malaria.17 The therapeutic 
response of this important active pharmaceutical ingredi-
ent (API), however, has been reported to be adversely 
affected by its erratic oral bioavailability due to its poor 
water solubility.18 Although this compound is a potent and 
lipid-soluble derivative of artemisinin,19,20 its poor water 
solubility (133±4 µg/mL) and low bioavailability (,40%) 
are considered to be major barriers to the development of a 
commercial dosage form.21
Currently, the commercially available dosage forms of 
ARTM are tablets, capsules, and injections. In addition to 
the poor water solubility, another issue associated with the 
parenteral formulations includes pain on injection, which 
leads to subsequent poor compliance.22 This pain might be 
caused by precipitation of the drug at the injection site. It 
is, therefore, important that a suitable dosage form needs 
to be designed, which addresses the issues of low aque-
ous solubility.
To date, a range of methods to address the issue of 
poor water solubility have been explored, including solid 
dispersions,23 solubilization,24 emulsions,25 microemulsions,26,27 
micronization,28 micelles,29 salts, liposomes,30,31 and inclusion 
complexes using cyclodextrin.32 The literature, however, sug-
gests that none of these approaches were particularly effec-
tive at addressing the issues of low aqueous solubility, while 
having other limitations around manufacturing complexity 
and physical stability.23,33–35
In this study, we report the use of an alternative 
approach for delivering drugs with low aqueous solubility. 
This involves the reduction of particle size of drugs down 
to submicron sizes. This provides the potential to drive 
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Figure 1 chemical structure of arTM.
Abbreviation: arTM, artemether.
Drug Design, Development and Therapy 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3839
artemether nanocrystals, antimalarial evaluation
dissolution through increasing the surface area of the drug 
that is in contact with the media.36–40
In this regard, Freundlich–Ostwald and other research-
ers have reported that reducing the radius of particles can 
lead to increased solubility.41–43 This enhanced solubility is 
more pronounced for particles ,1 µm.44 To the best of our 
knowledge, hitherto nanocrystals of ARTM, which is a very 
promising drug delivery approach, have not been reported. 
This article therefore discusses the utility of a novel size 
reduction system (Dena® DM-100) previously reported by 
Plakkot et al45 for the rapid production of smart nanocrystals 
of ARTM with enhanced dissolution, solubility, long-term 
physical and chemical stability, and enhanced in vitro and 
in vivo antimalarial performance, against the dominant 
malaria-causing species in Pakistan, which include P. vivax 
and P. falciparum.
Materials and methods
Materials
ARTM was kindly gifted by the Shanghai Institute of 
Material Medica, Shanghai, China (batch no: 110916 from 
Chengdu Wagott Pharmaceutical Co., Ltd., Chengdu, China), 
hydroxypropyl methylcellulose (HPMC 6cps, batch no: 
8028213) and polyvinylpyrrolidon (PVP-K30, batch no: 
08297052G0) were purchased from BASF (Ludwigshafen, 
Germany), sodium lauryl sulfate (SLS) (batch no: 08421LE) 
was purchased from Sigma-Aldrich (St Louis, MO, USA). 
Distilled water was produced in the University of Bradford 
laboratories.
Preparation of arTM nanosuspension
ARTM nanosuspensions were produced using the Dena® 
(DM-100 size reduction machine.46 This machine is composed 
of fast-moving conical rotor inside a conical sleeve. The 
grinding media (0.2 µm, yttrium-reinforced zirconium beads) 
housed inside indentations in the conical rotor and the narrow 
gap between the rotor and outer sleeve. Turbulence and high 
shear generated within the narrow gap provides potential 
for shearing and rupturing the particles, which results in the 
production of ultrafine powders in the submicron size range. 
The processed suspension continuously recycles through 
the apparatus through a stainless steel screen that prevents the 
contamination of product and retains the grinding media.
ARTM powder was suspended in 250 mL of an aqueous 
solution consisting of HPMC 6cps (0.5%, w/w), PVP-K30 
(0.5%, w/w), and SLS (0.1%, w/w). ARTM suspensions were 
produced at the concentrations of either 2.5% (w/w) or 10% 
(w/w). In both suspensions, with solid loads of 2.5% and 10%, 
the pH was adjusted to 2.0 using HCl. In addition, the impact 
of milling time on particle size distribution of the ARTM 
was investigated at both low and high solid loads (2.5% and 
10%). The suspensions were processed for 60 minutes by 
recycling through the size reduction chamber. Samples were 
collected periodically using the sampling port, and particle 
size was measured using the Zetasizer Nano-ZS instrument 
(Malvern Instruments, UK), at the intervals of 5, 10, 15, 30, 
45, and 60 minutes.
characterization of arTM nanocrystals
Particle size measurement
Particle size of the ARTM nanosuspensions was determined 
using dynamic light scattering (DLS), Zetasizer Nano-ZS 
instrument. For 10% (w/w) nanosuspension, 1 mL of the 
sample was further diluted in water (1:3). Sample analysis 
of the low feed nanosuspension (2.5%, w/w) was, however, 
carried out without further dilution. For all measurements, 
water was selected as dispersant, and temperature was kept as 
25°C. Disposable sizing cuvettes were used for the analysis of 
all samples; all measurements were made in triplicate (n=3), 
and results were reported as mean ± SD.
Zeta potential measurements
The zeta potential of nanosuspensions was determined 
using the Zetasizer Nano-ZS instrument. The samples for 
zeta potential measurements were prepared according to 
the reported method of Plakkot et al.45 The original samples 
of the produced nanosuspensions were further diluted in the 
dispersion medium. One milliliter of the sample was taken 
for 2.5% nanosuspension, while only 0.2 mL of 10% (w/w) 
formulation was used, which was further diluted in 10 mL 
of the dispersion medium. All the samples were analyzed in 
triplicate (n=3), and results were presented as mean ± SD.
Determination of the loading content of arTM
The nanosuspensions were evaluated for active content using 
a Waters 2695, high performance liquid chromatography 
(HPLC) system connected to the ultraviolet detector. The 
Ultra™ II (C18 5 µm, 250×4.6 mm column) was used, and 
the temperature was set at 30°C. The solvent system used as 
the mobile phase for ARTM assay consisted of acetonitrile 
and buffer (20:80, v/v; 5 mL of triethylamine diluting to 100 
by using water), and the pH was adjusted to 3±0.05 with 
orthophosphoric acid. The flow rate of the mobile phase was set 
at 1 mL/min and was analyzed at a wavelength of 216 nm.
scanning electron microscopy (seM)
The morphology of unprocessed ARTM was evaluated using 
the SEM (Quanta 400 SEM; FEI Company, Cambridge, UK). 
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ARTM images were taken at various magnifications. The 
particles of ARTM were sputter coated with gold prior to the 
morphological studies.
Transmission electron microscopy (TeM)
TEM (TEM-1200Ex; Japan Electron Optics Laboratory 
Corporation, Tokyo, Japan) was used to evaluate ARTM 
nanocrystals at 120 kV. Nanosuspensions of ARTM were 
deposited on 200 mesh copper grid, which was coated with 
formvar/carbon (code no: S162), followed by drying the 
samples at room temperature. The samples were stained 
negatively with the magnesium uranyl acetate (2%) solution 
due to the low conductivity of the API.
Differential scanning calorimetry (Dsc)
The melting point and heat of fusion of unprocessed and pro-
cessed ARTM was determined using DSC (Q2000 series; TA 
Instruments, New Castle, UK). The machine was calibrated 
with indium 99% (MP at 156.6°C) and zinc (MP at 419.5°C). 
Under the stream of nitrogen gas, the raw powder and milled 
samples (nanocrystals) of ARTM were then scanned at a flow 
rate of 50 mL/min with temperature ranging from 25°C to 
200°C at a heating rate of 10°C/min.
Powder X-ray diffraction (PXrD) studies
Crystallinity of the raw and processed ARTM recovered 
from nanosuspensions was evaluated using the PXRD (D-8, 
powder diffractometer; Bruker, Kahsruhi, Germany). The 
samples loaded into silicon wells were scanned in the 5°–50° 
2θ range at the rate of 10 2θ/min, at wavelength 1.542 Å 
with 1 mm slit using Cu Kα as a radiation. The PXRD was 
calibrated using a corundum standard.
solubility studies
The solubility studies were also carried out for the ARTM 
nanocrystals. Samples were isolated from nanosuspensions 
at the concentration of 10% (w/w) by centrifugation using 
the method previously reported by Van Eerdenbrugh et al,47 
Gao et al,48 and Thakkar et al.49 Approximately 1.5 mL of the 
ARTM nanosuspension was filled into a centrifugation tube 
and stored for 24 hours. The sample was then centrifuged 
using a sigma centrifuge (model: Sigma 0II5982IIII; Scientific 
Laboratory Supplies Limited, Wilford, Nottingham, UK) at 
14,800 rpm for 1 hour. The supernatant layer was taken 
and filtered through 0.02 µm filter (syringe filter: 20 nm; 
Whatman International Ltd, Dassel, Germany) to ensure 
that any undissolved API .0.02 µm (eg, the nanoparticles) 
was separated from dissolved drug. The supernatant was 
then analyzed for the ARTM content using the HPLC 
method as previously described. The solubility study of 
unprocessed ARTM in pure water and stabilizer solution 
(HPMC, 0.5% [w/w]; PVP-K30, 0.5% [w/w]; SLS, 0.1% 
[w/w]) was also carried out to assess the nanocrystals effect 
on saturation solubility of ARTM. Sufficient quantity of 
ARTM in pure water and stabilizer solution was placed 
in vials and sonicated for 2 hours followed by the use the 
same procedure as mentioned for nanocrystals.
stability studies
Physical stability of the produced ARTM nanosuspensions 
was also carried out in the present study and was monitored 
by measuring particle size and zeta potential with time. 
Chemical stability of ARTM was assessed by the determi-
nation of the active content using HPLC for samples stored 
for 7 days both in acidic media and in water. In addition, 
the ARTM nanosuspension with high solids load (10%) was 
subjected to long-term (90 days) stability studies at 2°C–8°C, 
25°C, and 40°C. The purpose of this study was to determine 
the extent of the particle growth through aggregation and 
Ostwald ripening. The particle size of stored samples was 
monitored at regular intervals including 10, 15, 30, 45, 60, 
75, and 90 days using DLS.
Dissolution studies
The in vitro drug release of ARTM nanocrystals was 
compared with micronized ARTM (mean particle size 
8.0±2.50 µm) produced using the FPS Spiral Jetmill (FPS, 
Italy), raw ARTM API powder, marketed tablets (20 mg), and 
the microsuspension (6.0±3.0 µm) prepared by crushing the 
tablet using a pestle and mortar followed by sonication in the 
same dispersion medium used for ARTM nanosuspensions. 
Dissolution tests were performed using the USP apparatus II 
(paddle method) at 100 rpm, which has been reported by 
Umapathi et al.21 The dissolution medium (1,000 mL) chosen 
for dissolution testing was composed of phosphate buffer at 
pH 7.2 and 1% sodium dodecyl sulfate, which has previously 
been reported by Pawar et al.50
For determination of the amount of drug dissolved, 5 mL 
aliquots were collected from the dissolution bath at specified 
time intervals (0, 2, 5, 10, 15, 30, 45, and 60 minutes) at 
37°C±1°C using the syringe filter (0.2 µm). The dissolution 
media were then supplemented with 5 mL of fresh dissolu-
tion medium to maintain sink conditions. This small-size 
syringe filter has been previously reported as being effective 
for use in dissolution studies of nanocrystals.39,51 The drug 
content of each sample was analyzed using reverse phase 
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HPLC (the method has been described in the “Materials and 
methods” section).
Microbiological examination and in vitro  
antimalarial assay
Giemsa-stained smears were examined to identify the 
Plasmodium species by a skilled microbiologist of Teaching 
Hospital (Hayat Abad Medical Complex [HMC] Peshawar, 
Peshawar, Pakistan). In vitro antimalarial assays were under-
taken for the ARTM nanosuspension, unprocessed ARTM, 
and marketed tablets (20 mg) against identified species, 
ie, P. falciparum and P. vivax. The culture was maintained 
as described by Trager and Jensen.52 Stock solutions of 
the ARTM were prepared in solvent at concentrations of 
0.1–20 ng/mL for the ARTM nanosuspension, unprocessed 
ARTM, and marketed tablets with the concentrations of 
1–70 ng/mL. The culture (P. vivax 2%–3% and hematocrit 
2%–3%) was exposed to various concentrations of the 
nanosuspensions, unprocessed API, and marketed tablets 
for 72 hours (37°C, 5% CO
2
). Lytic buffer comprising Tris 
pH 7.5 (20 mM), EDTA (5 mM), saponin (0.008%), triton 
X-100 (0.08%), and syber green-I was added to each well 
followed by incubation for 3 hours in the dark in incubators 
at room temperature. Parasites in the thin films were counted 
against 250 erythrocytes each, with slides being read in 
triplicate. The mean parasitemia was calculated from the 
triple-read replicate tests.
The mean parasitemia in the drug-free control wells 
served as the parameter of optimum and relative growth 
inhibition in the drug wells and was calculated on the basis 
of formula as suggested by Fidock et al.53 All the plates were 
read under fluorescence and IC
50
 was determined.
Activity
Mean parasitemia treated
Mean parasitemia cont
= −100
rol
×100



 
(1)
in vivo antimalarial activity
In vivo studies were carried out according to the ethical 
committee of the University of Malakand and relevant 
Bye-Laws 2008 (Scientific Procedure Issue-1). In house, 
male Swiss albino mice aged between 4 weeks and 6 weeks 
with body weight 30±5 g were used. The protocol for in 
vivo studies was designed based on the 4 days suppressive 
studies of Peters.54
P. vivax (HMC-147) collected from the Teaching Hospital 
was used. Experimental animals were infected by introduc-
ing parasitemia intraperitonealy at concentrations of 106 by 
diluting mice blood in buffer using acid citrate dextrose. 
The animals were divided into ten groups (n=6 per group). 
After postinfection starting from day 0 to day 3, ARTM 
nanosuspensions, microsuspensions, marketed tablets 
(20 mg), and unprocessed API (raw powder) were given in 
the form of a suspension by oral gavage at concentrations of 
2 mg/kg. Blood was withdrawn from the tail vein on day 4 
postinfection. Methanol was used to fix the blood smear 
followed by staining with Giemsa stain. In the experiment, 
untreated control mice were used to check any change in the 
susceptibility of host for infection and for procedural errors. 
Parasites were counted from each slide as percent paracitemia 
after counting 250 red blood cells using the formula reported 
by Fidock et al.53
acute toxicity studies of arTM nanosuspension
Acute oral toxicity studies were conducted for ARTM 
nanosuspensions to estimate the lethal dose (LD
50
) using 
male Swiss albino mice (n=8) weighing 35±5 g. ARTM 
nanosuspensions were given in several doses (500, 1,000, 
1,500, and 2,000 mg/kg) by oral gavage. The doses were 
decided as per the main test specified in the Organization for 
Economic Cooperation and Development Guideline 420.55 
After administering the ARTM nanosuspensions at the above 
doses, the toxic effects and number of deaths were observed 
over the period of 24 hours. The protocol for this study was 
carried out according to the requirements of, and approved 
by, the Ethical Committee of the University of Malakand and 
relevant Bye-Laws 2008 (Scientific Procedure Issue-1).
statistical analysis
Data were presented as mean ± SD. Data were analyzed using 
either paired t-tests or independent t-test and analysis of vari-
ance (ANOVA) followed by Tukey’s post hoc analysis. For 
particle size, zeta potential, drug content, solubility, stability, 
and dissolution studies, a P-value of ,0.05 was considered 
to indicate a significant difference between the tested groups. 
Dissolution data for the different formulations were also ana-
lyzed using Statistics 8.1 software (Tallahassee, FL, USA).
Results and discussion
Preparation of arTM nanocrystals and 
the impact of processing conditions
The initial size of the unprocessed ARTM was in the size 
range of 25–30 µm and 120–135 µm (Figure 2A). Figure 2C 
shows a rapid size reduction of ARTM 800–900 nm within 
the first 5 minutes of milling at different processing condi-
tions. It became evident that a processing time of 45 minutes 
was sufficient to achieve maximum attainable size reduction 
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of the particles. The average size of the particles and poly-
dispersity index (PDI) of ARTM for the high concentration 
suspension (10%, w/w) were found to be 161.3±1.5 nm and 
0.172±0.01, respectively, after 60 minutes (Figure 2C). For 
the low concentration feedstock (2.5%, w/w) prepared both 
in water and at acidic pH (2.0), the particles were reduced 
to sizes ,250 nm within 60 minutes. The average particle 
size and PDI values were shown to be 245.5±2.0 nm and 
0.150±0.02, respectively (Figure 2C). TEM images clearly 
show uniform size distribution of the ARTM nanocrystals 
with size ,200 nm (Figure 2B). All the particles shown 
in TEM images appear to show a defined morphology 
typically associated with crystalline material with no 
spherical particles present. The high concentration ARTM 
suspension (10%, w/w) showed the smallest particle size of 
161.3±1.5 nm compared to those from the low concentration 
feedstock (2.5%, w/w), which had shown an average particle 
size of 245.5±2.0 nm (Figure 2C).
Stenger and Peukert56 reported that, in wet milling pro-
cesses, increasing the milling time increases the shear stress, 
resulting in further reduction in the particle size. In concen-
trated suspensions, the high stresses and self-attrition forces 
can potentially cause greater size reduction compared to the 
dilute suspensions. Furthermore, particles are more likely 
to collide and interact with the milling medium (beads) 
resulting in more efficient size reduction. Smaller particles 
have therefore been achieved for the higher concentration 
suspension.
The HPLC results show that no new peaks relating to 
degradation products were observed on the chromatograms. 
Furthermore, no substantial aggregation or crystal growth 
was observed for the nanosuspensions prepared at acidic 
pH (2.0) when stored for 7 days. This suggests that the nano-
crystals will remain stable during residence in the stomach 
following administration of the nanosuspensions to humans, 
for which typical stomach residence time (20 minutes on an 
empty stomach) is far shorter than the period over which 
stability was monitored (7 days) (Table 1).
The percentage of the active agent content of ARTM 
nanosuspensions (2.5%, w/w) and (10%, w/w) in both water 
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Figure 2 scanning electron micrographs of unprocessed arTM (A); transmission electron micrographs of arTM nanocrystals (B); impact of milling time on particle size 
reduction (C); and Zeta potential values of different arTM nanocrystals (D).
Abbreviation: arTM, artemether.
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and acidic pH 2.0 was monitored for 7 days. For all four 
formulations, the percent recovery of the active content did 
not change significantly (Table 2), which shows that the 
stability of the drug substance in nanosuspension form is 
adequate under the conditions tested. In addition, no deg-
radation was observed for both high and low concentration 
nanosuspensions of ARTM in water and at acidic pH 2.0 
over 7 days (Table 2).
Measurements of zeta potential have also been reported 
to predict physical stability of formulated nanosuspensions. 
The zeta potential measurements are dependent on both the 
surface chemistry of the drug particles and the composition of 
the stabilizer medium. A range of zeta potential values have 
previously been reported to give stable nanosuspensions, 
which include ±30 mV and ±20 mV for electrostatically and 
sterically stabilized systems, respectively.57,58 In addition, 
a minimum zeta potential value of ±20 mV has been pro-
posed to deliver adequate stability of nanosuspensions when 
using both ionic and nonionic polymers and surfactants as 
stabilizers.59
In this study, the values of zeta potential of ARTM 
nanosuspensions were found to be within the reported range 
(±20 mV) (Figure 2D). No significant differences were 
observed between the tested formulations.
The zeta potential results demonstrated that the combina-
tion of HPMC 6cps, PVP, and SLS is sufficient to stabilize 
nanosuspensions at the selected concentrations. This com-
bination of polymers and surfactants has previously been 
shown to stabilize drug nanocrystals manufactured using 
the same top down manufacturing technology.60 In addition, 
Khan et al reported that the combination of HPMC, PVP, 
and SLS was very effective at stabilizing nanosuspensions 
with the excipients being adsorbed onto the surfaces of both 
crystallized and milled nanoparticles.39
Physical stability studies of ARTM nanocrystals at 
2°C–8°C, 25°C, and 40°C for 90 days demonstrated that 
nanocrystals stored at 2°C–8°C and 25°C (Figure 3A and B) 
showed improved stability compared to the samples stored 
at 40°C (Figure 3C). The nanocrystals stored at 2°C–8°C 
exhibited adequate stability (Figure 3A) with no marked 
changes in key nanosuspension characteristics. The nano-
suspensions stored at 2°C–8°C and 25°C maintained their 
PDI values, and there was no significant difference (P.0.05, 
paired t-test, one-way ANOVA) in the mean values of particle 
size after 90 days storage, which suggests that a homogenous 
particle size distribution has been achieved after milling, 
which facilitates the avoidance of Ostwald ripening in the 
nanosuspensions.61
Temperature has previously been reported to demonstrate 
marked influence on the physical stability of the suspen-
sions, with elevated temperatures increasing the kinetic 
energy of the suspended particles leading to increased 
interparticle interactions. The strong van der Waals forces 
acting between the nanoparticles lead to increased agglom-
eration and subsequent destabilization of the suspensions.62 
Freitas and Müller63 suggested that nanosuspensions should 
be stored at a temperature range of 2°C–8°C to achieve 
maximum stability.
Table 1 effect of various arTM concentrations (2.5% and 10%) in water and at ph 2.0 on the mean particle sizes (nm) of arTM 
nanocrystals in nanosuspension
Formulation conditions Average particle sizes of ARTM with ± SD (nm)
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Water concentration: 2.5% 245.5±0.21 247.5±0.31 248.45±0.01 249.0±0.02 249.5±0.13 250.25±0.12 250.65±0.01 251.25±0.21
ph (2.0) concentration: 2.5% 237.40±0.05 239.70±0.06 245.85±0.03 250.40±0.21 256.5±0.32 260.80±0.4 262.90±0.20 267.54±0.3
Water concentration: 10% 161.6±1.2 163.25±1.0 164.5±2.2 165.0±1.5 165.30±2.0 165.5±2.7 166.0±3.0 167.55±1.5
ph (2.0) concentration: 2.5% 154.75±2.3 158.23±3.2 163.58±2.0 170.87±3.0 178.44±1.5 180.76±1.0 185.74±2.5 188.57±1.2
Note: experiments were performed in triplicates (n=3), and data are presented as mean ± sD.
Abbreviations: arTM, artemether; sD, standard deviation.
Table 2 effect of various arTM concentrations (2.5% and 10%) in water and at ph 2.0 on active contents of arTM nanocrystals
Formulation conditions Active contents of ARTM nanocrystals (% active content ± SD)
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Water concentration: 2.5% 90.02±0.21 88.50±0.31 87.25±0.01 87.15±0.02 87.13±0.13 87.10±0.12 87.08±0.01 87.00±0.21
ph (2.0) concentration: 2.5% 89.50±0.05 88.45±0.06 88.28±0.03 88.20±0.21 88.18±0.32 88.12±0.4 88.10±0.20 88.05±0.3
Water concentration: 10% 92.05±1.2 89.75±1.0 89.50±2.2 88.52±1.5 88.38±2.0 88.25±2.7 88.20±3.0 88.10±1.5
ph (2.0) concentration: 10% 90.50±2.3 89.55±3.2 89.40±2.0 89.35±3.0 89.20±1.5 89.18±1.0 89.15±2.5 89.10±1.2
Note: experiments were performed in triplicates (n=3), and data are presented as mean ± sD.
Abbreviations: arTM, artemether; sD, standard deviation.
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Dsc and PXrD studies
DSC and PXRD results for the milled ARTM particles 
revealed that ARTM maintained its physical form and 
crystallinity after size reduction. For both nanocrystals and 
unprocessed ARTM, a single sharp melting endotherm was 
observed (Figure 4A). However, the melting temperature 
of the raw ARTM API appeared to show a slightly higher 
melting temperature (86.56°C) than the nanosuspensions 
(83.78°C). The endothermic peak of the processed samples 
was also slightly broadened. These differences can be caused 
by the particle size difference between the two samples. The 
DSC profile can be strongly affected by the particle size 
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Figure 3 Physical stability of arTM nanocrystals in terms of monitoring the particle size and PDi at various time points on storage at (A) 2°c–8°c, (B) 25°c, and (C) 40°c.
Abbreviations: arTM, artemether; PDi, polydispersity index.
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Figure 4 Dsc thermogram of milled and unprocessed arTM (A) and PXrD patterns of unprocessed and milled arTM (B).
Abbreviations: arTM, artemether; Dsc, differential scanning calorimetric; PXrD, powder X-ray diffraction.
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and packing density.64,65 Additionally, broadening of the 
DSC peaks can be caused by the presence of impurities or 
traces of the polymers remaining on the surface of the drug 
particles.65 The PXRD analysis of both unprocessed and 
processed ARTM produced sharp X-ray chromatograms, 
which confirmed that after milling ARTM maintained its 
crystalline nature (Figure 4B). However, PXRD peaks 
for the unprocessed samples showed greater intensity and 
sharper peaks.
These data suggested that both unprocessed ARTM and 
the particles isolated from the nanosuspension were crystal-
line in nature. The reduced intensity peaks observed for the 
milled ARTM are probably related to the smaller particle 
size of the samples coupled with the presence of traces of the 
amorphous polymeric stabilizing agent, which contributes to 
some diffuse scatter.38,39,66 Smaller particles are well known to 
demonstrate peak broadening with the reduced sharpness of 
peaks often leading to the disappearance of some peaks.64 In 
addition, the relatively small sample sizes used for the nano-
suspensions raise the risk that fewer particles are exposed to 
the X-rays, which in turn also leads to reduced peak intensity 
with lower resolutions of peaks.
solubility studies
The solubility profile of ARTM nanocrystals and unpro-
cessed ARTM in pure water and stabilizer solution is 
shown in Figure 5. The solubility of ARTM nanocrystals was 
found to be 900±2.4 µg/mL, giving an ~3–6-fold increase 
in solubility, compared to the solubility of unprocessed 
ARTM in stabilizer solution (321±2.0 µg/mL) and pure 
water (145±3.0 µg/mL). These differences in solubility were 
shown to be statistically significant (P,0.05, paired t-test, 
one-way ANOVA).
Despite water-soluble polymers and surfactants such 
as HPMC, PVP, and SLS being well known to increase 
the solubility of drug compounds,67,68 the comparison of 
the solubility profile of the nanosuspension with that of the 
unprocessed ARTM dissolved in these same surfactants 
clearly demonstrates that the nanocrystals provide a sub-
stantially increased saturation solubility of ARTM. This 
phenomenon we believe is ascribed to the marked reduction 
in particle size (=1,000 nm) and the greatly increased surface 
area of the particles.
Another possible explanation for the increase in solubility 
is the production of substantial surface amorphicity follow-
ing the particle being subject to a high energy comminution 
process. The results of DSC and X-ray studies, however, 
show that the ARTM remains predominantly crystalline 
after size reduction.
The impact of nanonization on the drug and its saturation 
solubility can be described by the following Freundlich–
Ostwald equation:69
 
S S
M
r RT
= α γ
ρ
exp
2


  
(2)
where S is the saturation solubility of nanoparticles, Sα is 
the saturation solubility of the large crystals, γ is the solid 
medium interfacial tension, M represents the molecular 
weight of the substance, r is the radius of particles, ρ rep-
resents the density, R is the gas constant, and T represents 
the temperature. According to this equation, drug solubility 
will be greater for reduced particle radius. However, Müller 
et al44 reported that this type of effect is not considerable for 
larger particles and is more pronounced for the particles in 
the submicron size range.
Dissolution studies
The results of comparative in vitro dissolution studies of 
different formulations of ARTM are shown in Figure 6. 
The figure shows a substantial increase in dissolution rate 
of the ARTM nanocrystals compared to the marketed tablets 
(20 mg), unprocessed API (raw drug substance), micro-
suspension (6.0±2.5 µm), and micronized ARTM powder 
(8.0±2.5 µm).
Figure 6 also shows that ~.70% of drug nanocrystals of 
ARTM are dissolved in the first 2 minutes compared to the 
unprocessed API (0.5%) and the commercial tablets (2.2%). 
Increases in the dissolution rate of 32- and 140-fold were 
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Figure 5 solubility studies of arTM nanocrystals, unprocessed arTM in pure 
water, and stabilizer solution.
Abbreviation: arTM, artemether.
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observed for nanocrystals compared to the commercial tab-
lets (20 mg) and unprocessed ARTM powder, respectively. 
This significant (P,0.05, paired t-test, one-way ANOVA) 
increase in the dissolution rate of ARTM nanocrystals dem-
onstrated that ARTM nanocrystals maintained their surface 
area with no marked agglomeration occurring after comple-
tion of the size reduction process.
The relationship of surface curvature, vapor pressure, and 
the particle size can be illustrated by the following Kelvin 
equation:
 
Ln
P
P
Mr
rRT
r
∞
= 2γ
ρ
 
(3)
where P
r
 is the vapor pressure of a particles having the 
radius r. P∞ is the vapor pressure of an infinitely large par-
ticle, γ  is the surface tension, R is the gas constant, T is the 
absolute temperature, M represents the molecular weight, and 
ρ is the density of the particle. Based on this mathematical 
expression, nanosized particles having larger surface curva-
ture demonstrate noticeably higher vapor pressure compared 
to the bigger micronized particles. Molecular transfer from 
liquid to gas is similar to the transfer of molecules from solid 
phase to liquid medium. In this case, the dissolution pressure 
can be converted to vapor pressure that is expected to be 
enhanced for smaller submicron particles.70
In addition to the enhanced solubility of nanosized 
particles, the following Prandtl equation demonstrates an 
important relationship between particle size and hydrody-
namic boundary layer (hH);
 hH = k L V( / )
/ /1 2 1 2
 (4)
where hH is the hydrodynamic boundary layer, k is a constant, 
L is the length of the surface in the direction of the fluid flow, 
and V is the relative velocity of the liquid surrounding the 
particles.71 When used in combination with the following 
Noyes–Whitney equation, it is clear that dissolution velocity 
will have a tendency to increase with reducing the diffusion 
boundary thickness:
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(5)
where dc/dt is the rate of drug dissolution, A is the drug sur-
face area accessible for dissolution, D is the drug diffusion 
coefficient, C
s
 is the saturation solubility of the drug, C
x
 is 
the bulk concentration, and h is the thickness of the boundary 
layer adjacent to the dissolving drug surface.
in vitro antimalarial activity
P. falciparum and P. vivax were confirmed using optical 
microscopy. The in vitro antimalarial activity of ARTM 
nanocrystals showed significant (P,0.05) activity against 
P. falciparum and P. vivax at the very low concentrations of 
0.7 ng/mL and 0.3 ng/mL, respectively (amount of ARTM 
in nanosuspension was 10%, w/w). However, the vehicle/
control comprising aqueous stabilizer (HPMC 6cps, PVP-
K30, and SLS) solution showed no activity against the tested 
strains. The IC
50
 values of the ARTM nanosuspension against 
P. falciparum and P. vivax were 28- and 54-fold lower than 
those of the unprocessed ARTM (20.0 ng/mL and 16.3 ng/mL) 
and 13- and 21-fold lower than those of the marketed ARTM 
tablets (9.0 ng/mL and 6.3 ng/mL), respectively. The 
enhanced in vitro performance of nanoformulation against the 
selected strains (P. falciparum and P. vivax) is encouraging, 
and it is because of the smaller particle size, which provides 
immense surface area resulting in an enhanced dissolution 
rate and consequently marked absorption.72
in vivo antimalarial activity
The in vivo antimalarial potential of ARTM with respect to 
antimalarial activity and reduction in the total parasitemia for 
a range of different pharmaceutical presentations including 
nanocrystals, unprocessed API, and marketed tablets is 
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Figure 6 Comparative dissolution profile of ARTM nanocrystals, microsuspension, 
micronized drug, marketed tablets, and raw arTM.
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shown in Figure 7A and B. As shown in Figure 7A, the 
highest parasitemia was observed in control group on day 4 
(receiving vehicle). The highest parasitemia observed in the 
control group confirmed that the chosen animal model for 
the current study was valid and accurate.
The different ARTM presentations demonstrated sig-
nificant antimalarial performance compared to the control 
group. ARTM nanocrystals showed (P,0.05) the highest 
reduction in the percent parasitemia (89%) in the treated ani-
mals compared to the microsuspension, unprocessed API, 
and marketed ARTM formulation. The unprocessed API, 
marketed tablets, and microsuspension were, however, 
only able to reduce the paracitemia by 27%, 45%, and 60%, 
respectively, at same dose (2 mg/kg). The antimalarial activ-
ity of ARTM nanocrystals was 3.2-, 2-, and 1.5-fold higher 
than that of the unprocessed API, marketed formulation, 
and microsuspension with no significant difference in the 
survival of experimental animals receiving ARTM nanocrys-
tals, unprocessed API, and marketed ARTM formulations 
(Table 3). These data suggest that the therapeutic window 
of this drug is reasonably high.
The enhanced antimalarial efficacy of ARTM nano-
crystals is probably related to the rapid dissolution of the 
high surface area of nanoparticles in vivo, with the oral 
bioavailability likely to be highest for this system in line 
with hypotheses described in the literature.72 In this regard, 
the dose of ARTM in nanocrystals form has the potential to 
be reduced which in turn could potentially reduce the dose-
related toxicity of this drug, with the additional opportunity 
to ameliorate the dose-related resistance problems, which 
are well known for this very potent drug.
acute toxicity
LD
50
 (median lethal oral dose) is a statistically derived 
single dose of a substance that can be expected to cause 
death in 50% of treated animals when administered by the 
oral route. The LD
50
 value is expressed in terms of weight 
of test substance per unit weight of test animal (milligram 
per kilogram). In the acute toxicity studies, no mortality was 
observed in the groups receiving 500, 1,000, and 1,500 mg/kg 
dose of both ARTM nanosuspensions after 24 hours. How-
ever, animals of the group receiving 2,000 mg/kg were 
shown to be deceased. It can therefore be concluded that 
the LD
50
 value of ARTM nanocrystals is between 1,500 mg/
kg and 2,000 mg/kg when given orally. The LD
50
 value of 
ARTM was previously reported by Zhou et al,73 which was 
found to be .2,000 mg/kg. The high LD
50
 value of ARTM 
conventional dosage form could be due to its low solubility 
and hence low bioavailability as compared to nanoformula-
tion, which has also become evident in our solubility and 
dissolution studies.
Conclusion
A novel top down technology (Dena® DM-100) was shown 
to be very effective at producing ARTM nanocrystals 
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Figure 7 Monitoring of percent parasitemia (A) and antimalarial activities (B) in different groups of mice using arTM nanocrystals, microsuspension, marketed formulation, 
and unprocessed arTM.
Abbreviation: arTM, artemether.
Table 3 number of swiss albino mice to survive between the 
different groups at 2 mg/kg (arTM)
Groups Number of mice alive 
by day 5
control/arTM unprocessed 3/8
arTM nanosuspension 6/8
arTM microsuspension 4/8
arTM marketed formulation 4/8
Abbreviation: arTM, artemether.
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(,300±2.5 nm) over a short duration (,30 min), with high 
drug concentrations and improved saturation solubility 
achieved for both the high concentration (10%, w/w) and 
low concentration (2.5%, w/w) nanosuspensions.
The smallest average particle size of ARTM (,170± 
2 nm) was achieved in 60 minutes for the high concentration 
suspensions (10%, w/w) when processed both in water and 
at pH 2.0. The combination of HPMC 6cps (0.5%, w/w), 
PVP-K30 (0.5%, w/w), and SLS (0.1%, w/w) was sufficient 
to stabilize the nanocrystals in suspension. The nanocrystals 
showed much increased dissolution rate with ~32- and ~140-
fold enhancement in the dissolution rate compared to the 
marketed tablets and the raw unprocessed ARTM.
In both the in vitro and in vivo studies, the antiplas-
modial activity of the produced ARTM nanocrystals is 
compared favorably with that of the raw unprocessed API 
and the marketed tablet product. The nanocrystals of ARTM 
demonstrated 3.2-, 2-, and 1.5-fold higher activity against 
the selected strains (P. vivax) compared to those of the 
unprocessed API, marketed tablets, and microsuspension, 
respectively. Moreover, the nanocrystals of ARTM also 
demonstrated 28- and 54-fold lower IC
50
 values compared to 
those of the unprocessed API and marketed ARTM tablets, 
respectively, against P. falciparum, while also demonstrating 
13- and 21-fold improvements for the same presentations 
against P. vivax.
These data clearly demonstrate that the nanocrystals of 
ARTM produced using a top down size reduction technology 
have superior physicochemical characteristics, which lead 
to improved in vivo antimalarial performance, compared 
to those of unprocessed API, micronized drug, and com-
mercially available ARTM tablets. The produced ARTM 
nanocrystals demonstrated rapid in vitro dissolution, which 
provided benefits in vivo drug absorption and resultant 
improved in vivo antiplasmodial activity.
This study clearly demonstrated that the Dena® DM-100 
system is able to rapidly and efficiently reduce the particle size 
to the level at which the dissolution rate and bioavailability 
of ARTM are enhanced markedly. These results suggest 
that the ARTM nanocrystal preparation could have the 
potential to demonstrate improved therapeutic performance 
in humans; hence, future work will be focused on completing 
the experimental studies, which could provide a line of sight 
to the clinical evaluation of the nanocrystal system.
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